UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in JANX — Janux Therapeutics, Inc.

CIK 861177 NEW YORK, NY

Back to JANX Full portfolio

Position in JANX

as of Mar 31, 2026 · filed May 13, 2026 Compact

Position Value

$1,219,820

+$177,950 QoQ

Shares Held

87,757

+16.2% QoQ

Ownership

0.144%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 61% Shared 0% None 39%

Common Shares in JANX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,037,771 across 211 Biotechnology names. JANX ranks #119 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	3,057,396	$1,365,249,602
2	REGN	Regeneron Pharmaceuticals, Inc.	723,621	$559,098,523
3	ALNY	Alnylam Pharmaceuticals, Inc.	677,519	$224,170,706
4	INSM	INSMED Inc	1,215,025	$198,680,883
5	RPRX	Royalty Pharma plc	3,095,766	$148,503,890
6	INCY	Incyte Corp	1,540,913	$145,030,725
7	IONS	Ionis Pharmaceuticals Inc	1,475,632	$110,805,201
8	DNLI	Denali Therapeutics Inc.	4,432,314	$85,100,425

All Filings in JANX

Export CSV

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,219,820	87,757	+16.2%	Shares	Defined	2026-05-13
2025-12-31	$1,041,870	75,498	+13.8%	Shares	Defined	2026-02-13
2025-09-30	$1,620,981	66,325	-40.4%	Shares	Sole	2025-11-14
2025-06-30	$2,572,462	111,362	-40.3%	Shares	Defined	2025-08-14
2025-03-31	$5,032,638	186,394	+12.5%	Shares	Defined	2025-05-19
2024-12-31	$8,873,556	165,737	+532.7%	Shares	Defined	2025-02-14
2024-09-30	$1,189,992	26,194	-13.2%	Shares	Defined	2024-11-14
2024-06-30	$1,264,155	30,178	+247.1%	Shares	Defined	2024-08-14
2024-03-31	$327,366	8,695	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.